BRAF INHIBITORS AS A THERAPEUTIC OPTION FOR AMELOBLASTOMA: LITERATURE REVIEW

Abstract

Ameloblastoma is a benign odontogenic tumour that mainly affects the mandible and, in some cases, the maxilla. Traditionally, standard treatment for ameloblastoma involves radical surgery, such as wide resection with a safety margin and subsequent reconstruction. However, due to the complications of the surgical approach, with recent advances in research, there has been growing interest in the pathogenesis of this neoplasm and the high incidence of the BRAF V600E mutation in ameloblastomas has been identified, allowing the use of BRAF inhibitor medications in experimental therapies. Thus, the present review aims to raise the aspects and challenges faced in the insertion of an experimental target therapy with BRAF inhibitor medication for the conservative treatment of ameloblastoma. To obtain the necessary content, this article reviews databases PubMed, ScienceDirect, Medical Literature Analysis and Retrieval System Online (MEDLINE) and Google Scholar, considering the descriptors: Ameloblastoma, B-raf Kinase, Vemurafenib, Dabrafenib and Targeted Therapy. After collecting the information, it was possible to conclude that therapy with Dabrafenib or Vemurafenib was advantageous in terms of quality of life, adverse effects, progression-free survival of the patient, as well as the notable reduction in the diameter of the tumours and further investigation is essential a clinical and molecular level to advance the precision of ameloblastoma management.